Table 2. Vaccine Completion in 1 and 2 Months by Scheduling Modality.
| Modality | No. | Dose completion at 1 mo | Dose completion at 2 mo | Series completion at 2 moa | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Completion, No. (%) [95% CI] | Difference, % (95% CI) | P valueb | Completion, No. (%) [95% CI] | Difference, % (95% CI) | P valueb | Completion, No. (%) [95% CI] | Difference, % (95% CI) | P valueb | ||
| Outbound telephone call only | 390 | 14 (3.6) [1.7 to 5.4] | NA | NA | 16 (4.1) [2.1 to 6.1] | NA | NA | 13 (3.3) [1.6 to 5.1] | NA | NA |
| Text plus outbound telephone call | 7890 | 243 (3.1) [2.7 to 3.5] | −0.5 (−2.4 to 1.4) | .57 | 315 (4.0) [3.6 to 4.4] | −0.1 (−2.1 to 1.9) | .91 | 222 (2.8) [2.4 to 3.2] | −0.5 (−2.3 to 1.3) | .55 |
| Text plus inbound telephone call | 7765 | 253 (3.3) [2.9 to 3.7] | −0.3 (−2.2 to 1.6) | .72 | 342 (4.4) [3.9 to 4.9] | 0.3 (−1.7 to 2.3) | .78 | 231 (3.0) [2.6 to 3.4] | −0.4 (−2.2 to 1.5) | .69 |
Abbreviation: NA, not applicable.
a
Completed 2 doses of the mRNA-1273 [Moderna] or BNT162b2 [BioNTech-Pfizer] vaccine or 1 dose of the Ad.26.COV2.S [Janssen] vaccine.
b
P < .025 was the threshold for statistical significance using the Bonferroni correction for multiple comparisons and a type I error rate of .05 (.05/2).